Contact
searchSearch
HMP Global
Login
Quiz

Niraparib Plus Dostarlimab for Patients With Germline BRCA1/2-Mutated TNBC

12/11/2025

Related Content

Kevin Kalinsky, MD
Videos
Frontline Sacituzumab Govitecan Continues to Show Benefit in PD-L1–Positive Triple-Negative Breast Cancer
06/24/2026
Kevin Kalinsky, MD, MS
Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...
Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...
Kevin Kalinsky, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Pembrolizumab Demonstrates Long-Term Survival Benefit in in Early-Stage Triple-Negative Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses final results from the KEYNOTE-522 study showing durable event-free and overall survival benefits with pembrolizumab plus chemotherapy in patients with stage 2/3 triple-negative breast cancer, confirming its...
Peter Schmid, MD, PhD, discusses final results from the KEYNOTE-522 study showing durable event-free and overall survival benefits with pembrolizumab plus chemotherapy in patients with stage 2/3 triple-negative breast cancer, confirming its...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology
Sara Tolaney, MD
Videos
Sacituzumab Govitecan Plus Pembrolizumab Delivers Benefit Independent of TROP2 Expression in Triple-Negative Breast Cancer
06/19/2026
Sara Tolaney, MD
Sara Tolaney, MD, discusses biomarker analysis results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab improved progression-free survival regardless of TROP2 expression, BRCA mutation status, or HER2 expression...
Sara Tolaney, MD, discusses biomarker analysis results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab improved progression-free survival regardless of TROP2 expression, BRCA mutation status, or HER2 expression...
Sara Tolaney, MD, discusses...
06/19/2026
Oncology
Videos
Moving Beyond Chemotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC): Are We Clinically Ready? Round 1
03/31/2026
Kelly McCann, MD, PhD; Seth Wander MD, PhD; Jason Mouabbi, MD
03/31/2026
Oncology

Recent News

News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use